Sionna Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-16.6%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$2.56next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Potential Phase 2b Dose-Ranging Study Initiation | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
SION-719 PreciSION CF Phase 2a Sweat Chloride Efficacy Bar Annually
Cash Runway Quarterly289.9MTarget: Fund operations into 2028
Quarterly Research and Development (R&D) Expenses Quarterly19M
Watch Items
- SION-719 PreciSION CF Phase 2a Topline Data ReadoutTrigger: Summer 2026Action: Evaluate safety, tolerability, pharmacokinetics, and sweat chloride changes to determine whether to prioritize the add-on strategy or advance the proprietary dual-combination program.
- SION-451 Phase 1 Dual Combination Trial Topline Data ReadoutTrigger: Summer 2026Action: Assess safety and tolerability of SION-451 in combination with SION-2222 and SION-109 in healthy volunteers to support Phase 2b dose-ranging study design.
- Liver Function Test (LFT) Elevations and Hepatotoxicity SignalsTrigger: Any clinically meaningful signal of drug-induced liver injury or serious adverse eventsAction: Re-evaluate the clinical viability of the NBD1 stabilizer pipeline, as safety signals could halt development or prevent FDA approval.
Research as of 20 Jun 2026